Hemostemix’s Pitch to Wall Street: ACP-01 Vascular Dementia Trial will Generate $5,365,000, Capture Data, as a Phase 1 Clinical Trial March 17, 2025 Read More »
Hemostemix and FireFly Neuroscience’s Brain Network Analytics (BNA™) Engage to Complete Phase 1 Vascular Dementia Clinical Trial of ACP-01 March 6, 2025 Read More »
Hemostemix PR Inc. Congratulates Luis Muñoz Marín International Airport on Achieving CEIV Pharma Certification February 11, 2025 Read More »
Hemostemix Contracts ProConsul to Ramp up Engagement with New Investors February 10, 2025 Read More »
